| | 156053-89-3 Basic information More.. |
| Product Name: | Alvimopan | | Synonyms: | 2-([(2S)-2-([(3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl)-3-phenylpropanoyl]amino)acetic acid;N-[(2S)-2-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-diMethyl-1-piperidinyl]Methyl]-1-oxo-3-phenylpropyl]glycine;2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-diMethylpiperidin-1-yl)propanaMido)acetic acid;AlviMopan (ADL 8-2698);170098-38-1 (Dihydrate);Alvimopan anhydrous;Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-;Ly246736 | | CAS: | 156053-89-3 | | MF: | C25H32N2O4 | | MW: | 424.53 | | EINECS: | 1312995-182-4 | | Mol File: | 156053-89-3.mol |  |
Use
Alvimopan has its chemical name being 2-[[(2S)-2-[[(3R, 4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-piperidin-1-yl] methyl]-3-phenyl-propionyl] amino] acetic acid dihydrate. It is a highly selective peripheral opioid antagonist which was jointly developed by the British company GlaxoSmithKline (GSK) and the United States Adolor company. In May 2008, it was approved by the US FDA for entering into market for applying to promote the recovering of the gastrointestinal function of patients who have been subject to colon or small intestine stage I resection anastomosis. Since the product can selectively inhibit the gastrointestinal opioid receptors without reducing the central analgesic effect of opioid agonists, therefore it does not affect the analgesic effect of systemic administration with safety and well-tolerance.
- Alvimopan
-
- US $110.00 / KG
- 2022-02-25
- CAS:156053-89-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1 ton
- Alvimopan
-
- US $12.56 / KG
- 2022-02-25
- CAS:156053-89-3
- Min. Order: 1Kg/Bag
- Purity: 99%
- Supply Ability: 20tons
- Alvimopan
-
- US $0.00 / KG
- 2021-11-15
- CAS:156053-89-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200000pcs
|
|
156053-89-3
Recommend Suppliers |
|